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medium term. Furthermore re-treatment is possible whilst 
maintaining a low-side-effect profile.
Conclusion Debate is ongoing about the clinical signifi-
cance of various levels of residual disease after focal ther-
apy and the exact threshold at which to call failure within a 
patient who has had focal therapy.
Keywords Focal therapy · Prostate cancer · Minimally 
invasive therapy · High-intensity focussed ultrasound · 
HIFU · Cryotherapy · Histology · Pathology · Trial design
Introduction
The emergence of focal therapy as a potential and major 
shift in the way we manage localised prostate cancer is a 
highly debated area of research in uro-oncology. Whilst 
the concept of the index lesion being the primary driver for 
progressive prostate cancer seems attractive and its abla-
tion seems logical, the wider acceptance of focal therapy, 
even using such ablative modalities as cryotherapy and 
high-intensity focused ultrasound (HIFU) seems limited 
and questioned. This is especially an issue when regula-
tory approvals are being considered for device approvals 
or an approval for an additional indication including the 
focal ablation of a lesion [1, 2]. However, focal therapy has 
been increasing in popularity, which is highlighted by the 
increasing number of focal cryotherapy cases registered in 
the Cryo Online Database (COLD). The number of focal 
procedures performed per year has increased from 1 in 
1999 to 293 in 2007 [3–5].
Currently, there is an array of treatment modalities being 
evaluated for the focal treatment of localised prostate can-
cer. Whilst the two in pole position are HIFU and cryother-
apy, having been used for focal therapy for a longer period 
Abstract 
Introduction Focal therapy has increasingly become an 
accepted treatment option for patients with localised pros-
tate cancer. Most follow-up protocols use a mixture of pro-
tocol biopsies or “for cause” biopsies triggered by a rising 
PSA. In this paper, we discuss the histological outcomes 
from these biopsies and their use in guiding subsequent 
management and trial development.
Methods We conducted a literature search and reviewed 
the post-treatment biopsy results from studies on focal 
HIFU and focal cryotherapy. We subsequently reviewed 
the results of three recently published consensus statements 
released discussing many of the issues concerning focal 
therapy.
Results Research suggests that 1 in 5 of all post-treat-
ment biopsies after focal therapy are positive. However, 
the majority of these seemed to be from the untreated por-
tion of the gland or met criteria for clinically insignificant 
disease. The histological outcomes from focal therapy 
are promising and confirm its effectiveness in the short to 
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of time, others under investigation include photodynamic 
and vascular-targeted photodynamic therapy (PDT/VTP) 
[6, 7], irreversible electroporation [8], radiofrequency abla-
tion [9], magnetic thermotherapy [10], convective thermal 
water vapour [11], injectable toxins [12] and focal brachy-
therapy [13]. The aim of all these technologies is to treat 
the index lesion within the prostate whilst leaving behind 
healthy non-cancerous tissue or non-significant disease.
One of the significant areas of debate relates to how suc-
cess or failure of focal therapy is assessed, regardless of 
which ablative modality is being delivered. The arguments 
for and against a number of outcome measures follow a 
common theme in all studies and considerations given for 
acceptance and approval for focal therapy. Established 
prostate-specific antigen (PSA) follow-up criteria used for 
whole-gland treatments such as ASTRO, Phoenix and the 
Stuttgart criteria, are difficult to apply to a patient after 
focal therapy as the untreated normal prostatic tissue will 
continue to secrete PSA. PSA kinetics and PSA nadir may 
play a role as PSA secretion from the cancerous lesion is 
larger than healthy prostate tissue, and Ahmed et al. [14] 
noted an 80 % decrease in PSA at 3 months after focal 
HIFU. This decrease persisted at 12 months. The more 
solid endpoints of metastases and death would require 
over a decade of follow-up due to the long natural history 
of even clinically significant prostate cancer. Insisting on 
such outcomes for changes in clinical practice or regula-
tory approvals would inevitably stifle innovation. Not only 
would these findings have limited external validity, reported 
after 10–15 years but would be prohibitively expensive and 
resource heavy. Other outcome measures, such as histologi-
cal outcomes, are clearly needed.
In this paper, we aim to first discuss the existing state-
of-the-art with respect to histological outcomes after focal 
therapy and how best to interpret these in clinical practice. 
The literature is mainly based on the two most widely used 
modalities of HIFU and cryotherapy. Secondly, we will 
discuss histological endpoints from a trial design point of 
view that might be met with wider acceptance or at the very 
least, form the premise for further debate.
Histological changes on radical prostatectomy 
specimens
HIFU 
In one of the very first proof of concept studies, Van Leend-
ers et al. assessed the histological changes in unilateral 
HIFU in men who subsequently underwent a radical pros-
tatectomy (RP) 7–12 days later. This study was set up in 
the early evaluation of HIFU using the ablate-excise study 
model to demonstrate that ablation can be achieved, whilst 
the investigators did not set out to fully ablate all tissue. 
Macroscopically, well-demarcated circular and ellipsoid 
lesions were seen. Microscopically, cell necrosis was seen 
within the core of the lesion, however, and not surprisingly, 
this was incomplete in six out of nine lesions. Haemor-
rhage with hyperplastic epithelium and reparative changes 
was also seen at the borders of the lesion [15].
Napoli et al. [16] performed a similar study in five 
patients with RP performed 7–14 days after HIFU treat-
ment. They also found extensive coagulative necrosis but 
with no viable tumour within or at the boundaries of the 
treated lesion. Subsequently, over time, there is develop-
ment of fibrosis and elastotic collagen (Fig. 1).
Both these studies observed the presence of multi-focal 
lesions outside of the treated lesion and thus emphasise 
the need for accurate pre-operative staging and disease 
localisation.
Cryotherapy
In 1991 Onik et al. [17] showed complete coagulative 
necrosis and accurate visualisation of the ice ball under 
transrectal ultrasound (TRUS) in six dogs treated with 
Fig. 1  Left image shows a Gleason 3 + 4 adenocarcinoma, middle image shows typical changes after HIFU with no discernible glands, viable 
cells or tumour with presence of fibrosis and elastotic collagen, right image shows recurrent adenocarcinoma after HIFU
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cryotherapy. Larson et al. examined exactly the effects of 
this technique for cryotherapy in five patients who were 
already scheduled to go undergo salvage prostatectomy 
2–3 weeks later. Histologically, squamous metaplasia of 
glandular epithelium with haemorrhage and a zone of coag-
ulative necrosis and devitalisation was seen spreading from 
a central core [18]. However, similar to the HIFU studies, 
incomplete cell death on occasions has also been noted 
with cryotherapy [19].
Post‑treatment biopsies
Earlier work with protocol-driven TRUS biopsies in 167 
out of 176 patients treated with whole-gland cryoabla-
tion showed persistent tumour in 38 %. However, in this 
study, the exact histological data and thus clinical signifi-
cance of the biopsy results were not mentioned [19]. Simi-
larly, Crouzet et al. [20] performed post-treatment biopsies 
in 774 patients from cohort of 1002 patients treated with 
whole-gland HIFU procedures. Overall, 37 % of these 
biopsies were positive.
Donnelly et al. also performed a randomized control 
trial (RCT) where 244 men with T2/3 prostate cancer were 
randomised to either whole-gland cryotherapy or radiother-
apy. At a median follow-up of 100 months, they found no 
difference in disease progression between the two groups. 
They also found a higher number of positive biopsies at 
36 months in the radiotherapy arm (28.9 compared–7.7 % 
with cryotherapy) [21].
Reviewing the results of eight studies assessing focal 
cryotherapy, 98/391 (25 %) of all post-treatment biopsies 
were positive [3, 22–28] (Table 1). No information on grade 
or location for the 42 positive biopsies from the COLD 
registry paper by Ward et al. was available. Thus, review-
ing the results from the remaining papers shows that 86 % 
(48/56) of positive biopsies were either from an untreated 
portion of the prostate or met with criteria of insignificant 
lesions (Gleason 3, ≤2 cores positive).
Six of these studies mentioned the initial method of 
diagnosis and only two used transperineal mapping biop-
sies whilst all the others relied on TRUS biopsies for pre-
operative planning. The two studies that did use mapping 
biopsies had a 13–19 % post-procedure positive biopsy rate 
[22, 27].
Similarly, from the six studies assessing biopsies after 
focal HIFU, 22 % (39/175) were positive [14, 29–33] 
(Table 2). Excluding the four positive biopsies from the 
paper by Muto et al., as no data on location or histological 
grade were available, 63 % (22/35) of the positive biopsies 
were either insignificant or from the untreated part of the 
gland (Table 2).
However, results such as these have to be interpreted 
with caution as they are from a heterogeneous group of 
for-cause, protocol-driven, bilateral or targeted biopsies. It 
would be expected that for-cause biopsies would be more 
likely to be positive as they are performed for a clinical 
suspicion of recurrence. However, studies that only con-
duct for-cause biopsies, means that those with stable PSAs 
are selectively not subjected to verification biopsies after 
treatment. If protocol biopsies are performed then these 
should be aimed at determining initial treatment success 
and thus should be targeted at the treated lesion. Addition-
ally, performing biopsies of untreated areas is not assessing 
treatment success but rather the accuracy of pre-operative 
assessment.
Eleven studies mentioned the subsequent management 
of 62 patients in total who had a positive post-treatment 
biopsy. 61 % (38/62) elected for redo focal therapy and 
31 % (19/62) chose active surveillance (AS), whilst 8 % 
(5/62) had either external beam radiotherapy (EBRT), 
RP or androgen deprivation therapy (ADT). The abil-
ity to retreat with curative intent without significant addi-
tional morbidity is a major advantage of focal therapy over 
whole-gland treatments such as RP or EBRT.
Berge et al. [34] recently published the results of 130 
patients undergoing a second HIFU procedure of which 19 
underwent a second redo session and one had a third ses-
sion. Overall, this group was formed from a cohort of 359 
patients and thus represented the 36.2 % who needed repeat 
treatment based on biochemical, histological or imaging 
(mpMRI) failure. No cancer-specific deaths were reported 
in this group. Fifty-six men (43 %) did fail a second time. 
Forty underwent TRUS biopsy and 22 were positive. 
Their results also showed that side effects were not greatly 
increased with an increase in pad usage from 2.7 to 9 % 
(p < 0.001) and no effect on potency (p = 0.9). Blana et al. 
[35] had also previously shown a minimal impact on qual-
ity of life with a second session of HIFU.
A significant portion chose AS, and there is indirect evi-
dence to suggest that this may be an acceptable option for 
patients with positive post-treatment biopsies. Data from an 
AS series of 450 patients diagnosed on TRUS biopsy (and 
therefore approximately 30 % of whom would have been 
true intermediate risk) shows a 10-year cancer-specific 
survival of 97.2 % with only five deaths. A recent update 
which now included 993 men with up to 16-year follow-
up showed a 15-year actuarial cancer-specific survival 
of 94.3 % [36, 37]. Another indirect source of evidence 
is studies assessing the outcomes from patients who have 
post-radiotherapy positive biopsies. 21–32 % of patients 
may have positive biopsies. The results show that although 
patients with a positive biopsy have a poorer outcome their 
5-year biochemical disease-free survival (bDFS) was still 
high at 83.3–93.8 % compared to 97.5 % for those with a 
negative biopsy [38]. In contrast though, Zelefsky assessed 
10-year oncological outcomes and found that the group 
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with positive biopsies had only a 3 % PSA relapse-free sur-
vival and a 69 % metastases-free survival compared to 59 
and 90 %, respectively, for patients with negative biopsies. 
Zelefsky did have a third group of patients who had posi-
tive biopsies showing severe treatment effect. This group 
did not have a significantly different outcome when com-
pared to those with negative biopsies [39]. Thus, a positive 
biopsy has to be reviewed carefully before a clinical signifi-
cance can be implied. Similarly, a positive surgical margin 
after RP does not always convey a poorer outcome [40].
Discussion and focal therapy trial design
Knowing this data, the questions that need be asked before 
designing an appropriate trial are “when to biopsy?”, “How 
to biopsy?” and “How to interpret the results?”.
It is accepted that a well-designed RCT is high-level evi-
dence upon which treatment decisions can be based. How-
ever, designing an appropriate prospective trial to assess 
the follow-up of patients after focal therapy carries its own 
challenges. Successfully randomizing men to different sur-
gical treatments in prostate cancer can be challenging.
The initial entry point would be from diagnosis of dis-
ease. The methodology for diagnosis is important. Pre-
operative TRUS biopsy has been shown to be inaccurate 
particularly when assessing patients for focal therapy. For 
instance, 23 % of patients having a template biopsy after 
a previous TRUS biopsy had upgrading, whilst 60 % were 
found to have bilateral disease [41]. Systematic transper-
ineal and MRI-guided biopsies have been shown to be 
equally accurate in detecting cancer [42, 43]. Thus, a simi-
lar principle should be applied to post-treatment biopsies. 
Most still perform systematic TRUS biopsies after treat-
ment that may under-sample the treated area and lead to 
detection of insignificant disease from untreated tissue.
To improve upon, these ultrasound–MRI fusion tech-
niques have been developed. There seems to be potential 
benefit of this technique over systematic TRUS biopsies 
with 67 % more significant disease detected; however, the 
benefit is less clear when comparing cognitive MRI target-
ing versus a fusion technique [44–46]. Wysock et al. [45] 
did not show a significantly increased cancer detection rate 
between the two techniques, but did find improved accu-
racy for smaller lesions with fusion biopsies. Whilst Cool 
et al. [46] showed a 100 % increased accuracy for sampling 
a clinically significant tumour with fusion targeting versus 
cognitive. Five millimetres of transperineal mapping biop-
sies is arguably still the gold standard though, with up to 
95 % accuracy when compared to RP specimens [47, 48]. 
Nonetheless, these require a general anaesthetic and due to 
the higher number of cores taken have a potentially higher 
side effect profile.
Subsequently, the clinical significance of disease needs 
to be reviewed before any treatment is offered. Gleason 6 
disease has been shown to rarely if ever lead to metasta-
ses and thus death [49–51]. Similarly, metastases are very 
rare with tumour volume <0.5 cc [52]. Combining this data 
from results from AS series where few deaths occur, it can 
be reasoned that low-volume Gleason 6 disease may not 
benefit from interventional treatment [36]. Thus, the ideal 
focal therapy candidate is likely to be men with Gleason 7 
and above disease or high-volume Gleason 6 cancer.
These same factors play a role following focal therapy. 
If a patient’s disease has been accurately classified pre-
operatively, then follow-up can consist of imaging and 
biopsies only targeted to the treated area. As previously 
mentioned, although various criteria exist for follow-up, all 
effectively conclude that a rising PSA can be used to guide 
further investigation for recurrence and timing of the post-
treatment biopsy. An additional factor to consider is the use 
of mpMRI to follow up treated lesions and thus triggers a 
biopsy if residual or recurrent disease is detected.
After focal ablation, there is a residual inflammation, 
necrosis and eventual fibrosis. Along with some of the data 
in our own series, Biermann et al. [53] found that detection 
of grading of cancer in biopsies taken 6 months post-HIFU 
was possible (unlike with radiotherapy); thus, it seems rea-
sonable that biopsies can be performed at least as early as 
6 months.
With respect to mpMRI a consensus meeting found that 
77 % of panellists felt that this is a reliable tool for follow-
up [54]. From the series of 42 men by Ahmed et al., nine 
patients were found to have a positive mpMRI, seven of 
whom had subsequent positive biopsies. Overall, there is 
some evidence to support the use of mpMRI as a method 
for follow-up, with it appearing to form an important part 
of multi-modal follow-up [55–58].
Subsequently, the clinical significance of post-proce-
dural biopsies needs to be considered. There is limited 
evidence to suggest that low-grade low-volume residual in-
treatment field cancer behaves in a similar way to patients 
with primary disease of the same pathology. Similarly, 
there is no data on the natural history of secondary low-
risk lesions. As mentioned previously, the safest option 
would be to apply the same principles as for AS and fol-
low up these patients with repeated imaging with biopsies 
as deemed necessary. From the reviewed cryotherapy and 
HIFU papers, redo focal treatment and AS appear to be the 
most common management options selected for patients 
with positive biopsies.
We subsequently reviewed the results of three recently 
published consensus statements released discussing many 
of these issues concerning focal therapy (Table 3) [59–61]. 
All consensus meetings and expert opinions are consid-
ered as level five evidence, and their findings should be 
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considered with this in mind. However, in the absence of 
high-level evidence, they present important opinions from 
experts in the field and highlight areas of uncertainty.
Donaldson et al. and Van den Bos et al. separately dis-
cussed inclusion and exclusion criteria and both consen-
sus groups agreed that high-volume Gleason 6 (>5 mm 
MCCL) and Gleason 7 disease are the optimal candidates. 
They discussed the importance of accurate pre-operative 
assessment using MRI-targeted or fusion biopsy methods 
prior to offering a patient treatment. They recommend pro-
tocol biopsies at 12 months post-treatment and that a rising 
PSA or suspicious MRI should also trigger a biopsy. The 
ultimate end point was a negative 12-month biopsy. How-
ever, there was differing opinion on whether these should 
only be targeted or also systematic or whether residual 
low-grade and low-volume cancer is considered treatment 
failure. Donaldson et al. mentioned that biopsies should be 
targeted rather than systematic in order to reduce sampling 
of untreated tissue, whilst Muller et al. (another consen-
sus group) commented that systematic biopsies are useful 
for surveillance of the untreated gland. Re-treatment was 
considered acceptable and Donaldson et al. commented 
that overall re-treatment rate should be below 20 % since it 
was argued that retreatment was a positive attribute of the 
strategy.
The final point to consider when designing such a trial is 
the comparator arm. The two most common radical whole-
gland treatments are radiotherapy or RP. Neither has been 
assessed head-to-head in a RCT. Retrospective reviews 
have shown surgery to have better oncological outcomes; 
however, even with the best matching, bias can never be 
fully excluded [62, 63].
The role of focal therapy will ultimately help decide the 
most appropriate comparator arm. We feel that the current 
role of focal therapy is similar to that of tissue preserva-
tion in almost all other solid organ cancers (bar ovarian), in 
that, it leads to a minimal decrease in quality of life for the 
patient whilst providing acceptable cancer control. At least 
in the short to medium term, the data suggest that focal 
therapy may be meeting these aims. However, few studies 
have long-term follow-up and a systematic review showed 
a varying bDFS of between 86.2 % at 8 years and 60 % at 
5 years [64].
Thus, in the first instance, patients with localised inter-
mediate- to high-risk disease should be compared to those 
undergoing radical treatment with either EBRT or RRP. 
The aim of this study would be to show non-inferiority for 
short- to medium-term oncological outcomes with a supe-
rior side effects profile. Repeat treatments are possible with 
focal therapy, and a second treatment would not be con-
sidered a treatment failure unless there was a significant 
reduction in the two outcome measures mentioned.
Conclusion
Research suggests that one in five of all post-treatment 
biopsies after focal therapy is positive. However, the major-
ity of these seemed to be from the untreated portion of the 
gland or met criteria for clinically insignificant disease. The 
histological outcomes from focal therapy are promising 
and confirm its effectiveness in the short to medium term. 
Furthermore, re-treatment is possible whilst maintaining a 
low side effect profile. Debate is ongoing about the clini-
cal significance of various levels of residual disease after 
focal therapy and the exact threshold at which to call fail-
ure within a patient who has had focal therapy.
Acknowledgments M. Emberton and H. U. Ahmed would like to 
acknowledge funding from the Medical Research Council (UK), the 
Pelican Cancer Foundation Charity, Prostate Cancer UK, St Peters 
Trust Charity, Prostate Cancer Research Centre the Welcome Trust, 
National Institute of Health Research-Health Technology Assess-
ment Programme and the US National Institute of Health-National 
Cancer Institute. M. Emberton receives funding in part from the UK 
National Institute of Health Research UCLH/UCL Comprehensive 
Biomedical Research Centre. M. Emberton and H. U. Ahmed receive 
funding from USHIFU, GSK and Advanced Medical Diagnostics for 
clinical trials. M. Emberton is a paid consultant to Steba Biotech and 
USHIFU. Both have previously received consultancy payments from 
Oncura/GE Healthcare and Steba Biotech.
Conflict of interest V. Kasivisvanathan is funded by a Doctoral 
Research Fellowship from the National Institute for Health Research. 
The views expressed in this publication are those of the authors and 
not necessarily those of the NHS, the National Institute for Health 
Research or the department of health.
Ethical standard This paper does not contain any direct clinical or 
patient data. All the studies reviewed had appropriate ethics commit-
tee approval and have therefore been performed in accordance with 
the ethical standards laid down in the 1964 Declaration of Helsinki 
and its later amendments.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. FDA (2014) Executive summary: Ablatherm® integrated imag-
ing high intensity focused ultrasound (HIFU). Meeting of the 
Gastroenterology and Urology Devices Panel. http://www.fda.
gov/downloads/AdvisoryCommittees/CommitteesMeetingMa-
terials/MedicalDevices/MedicalDevicesAdvisoryCommittee/
Gastroenterology-UrologyDevicesPanel/UCM406819.pdf
 2. Valerio M, Emberton M, Ahmed HU (2014) Re: Jarow et al: 
Drug and device development for localized prostate cancer: 
report of a Food and Drug Administration/American Urological 
963World J Urol (2015) 33:955–964 
1 3
Association public workshop (Urology 2014;83:975–979). Urol-
ogy 84(3):732–733
 3. Ward JF, Jones JS (2012) Focal cryotherapy for localized pros-
tate cancer: a report from the national Cryo On-Line Database 
(COLD) registry. BJU Int 109(11):1648–1654
 4. Ahmed HU (2009) The index lesion and the origin of prostate 
cancer. N Engl J Med 361(17):1704–1706
 5. Ahmed HU et al (2012) Do low-grade and low-volume pros-
tate cancers bear the hallmarks of malignancy? Lancet Oncol 
13(11):e509–e517
 6. Moore CM, Azzouzi AR, Barret E, Villers A, Muir GH, Barber 
NJ, Bott S, Trachtenberg J, Arumainayagam N, Gaillac B, Allen 
C, Schertz A, Emberton M (2014) Determination of optimal drug 
dose and light dose index to achieve minimally invasive focal 
ablation of localised prostate cancer using WST11-vascular-
targeted photodynamic (VTP) therapy. BJU Int. doi:10.1111/
bju.12816
 7. Moore CM et al (2011) Light penetration in the human pros-
tate: a whole prostate clinical study at 763 nm. J Biomed Opt 
16(1):015003
 8. Valerio M et al (2014) A prospective development study inves-
tigating focal irreversible electroporation in men with localised 
prostate cancer: nanoknife electroporation ablation trial (NEAT). 
Contemp Clin Trials 39(1):57–65
 9. Shariat SF et al (2005) Pilot study of radiofrequency interstitial 
tumor ablation (RITA) for the treatment of radio-recurrent pros-
tate cancer. Prostate 65(3):260–267
 10. Johannsen M et al (2007) Thermotherapy of prostate cancer 
using magnetic nanoparticles: feasibility, imaging, and three-
dimensional temperature distribution. Eur Urol 52(6):1653–1661
 11. Mynderse L, Dixon C, Cabanas C, Rijo Cedano E, Huidobro C, 
Larson T (2014) Novel convective thermal water vapor therapy 
for prostate cancer: uniquely suited to zonal anatomy of the pros-
tate—preliminary gross and microscopic findings using ex vivo 
and acute in vivo, surgical ablative studies. In: 7th international 
symposium on focal therapy and imaging in prostate and kidney 
cancer. Pasadena, LA, USA
 12. Meschenmoser K et al (2013) Targeting cancer with a bi-func-
tional peptide: in vitro and in vivo results. In Vivo 27(4):431–442
 13. Polders DL, Steggerda M, van Herk M, Nichol K, Witteveen T, 
Moonen L, Nijkamp J, van der Heide UA (2015) Establishing 
implantation uncertainties for focal brachytherapy with I-125 
seeds for the treatment of localized prostate cancer. Acta Oncol. 
doi:10.3109/0284186X.2014.995312
 14. Ahmed HU et al (2011) Focal therapy for localized prostate can-
cer: a phase I/II trial. J Urol 185(4):1246–1254
 15. Van Leenders GJ et al (2000) Histopathological changes asso-
ciated with high intensity focused ultrasound (HIFU) treatment 
for localised adenocarcinoma of the prostate. J Clin Pathol 
53(5):391–394
 16. Napoli A et al (2013) Real-time magnetic resonance-guided 
high-intensity focused ultrasound focal therapy for localised 
prostate cancer: preliminary experience. Eur Urol 63(2):395–398
 17. Onik G et al (1991) Percutaneous transperineal prostate cryosur-
gery using transrectal ultrasound guidance: animal model. Urol-
ogy 37(3):277–281
 18. Larson TR et al (2000) In vivo interstitial temperature mapping 
of the human prostate during cryosurgery with correlation to his-
topathologic outcomes. Urology 55(4):547–552
 19. Koppie TM et al (1999) The efficacy of cryosurgical ablation of 
prostate cancer: the university of California, San Francisco expe-
rience. J Urol 162(2):427–432
 20. Crouzet S et al (2014) Whole-gland ablation of localized prostate 
cancer with high-intensity focused ultrasound: oncologic out-
comes and morbidity in 1002 patients. Eur Urol 65(5):907–914
 21. Donnelly BJ et al (2010) A randomized trial of external beam 
radiotherapy versus cryoablation in patients with localized pros-
tate cancer. Cancer 116(2):323–330
 22. Barqawi AB et al (2014) Targeted focal therapy for the manage-
ment of organ confined prostate cancer. J Urol 192(3):749–753
 23. Bahn D et al (2012) Focal cryotherapy for clinically unilateral, 
low-intermediate risk prostate cancer in 73 men with a median 
follow-up of 3.7 years. Eur Urol 62(1):55–63
 24. Truesdale MD et al (2010) An evaluation of patient selection cri-
teria on predicting progression-free survival after primary focal 
unilateral nerve-sparing cryoablation for prostate cancer: recom-
mendations for follow up. Cancer J 16(5):544–549
 25. Lambert EH et al (2007) Focal cryosurgery: encouraging health 
outcomes for unifocal prostate cancer. Urology 69(6):1117–1120
 26. Ellis DS, Manny TB Jr, Rewcastle JC (2007) Focal cryosur-
gery followed by penile rehabilitation as primary treatment 
for localized prostate cancer: initial results. Urology 70(6 
Suppl):9–15
 27. Onik G et al (2007) “Male lumpectomy”: focal therapy for pros-
tate cancer using cryoablation. Urology 70(6 Suppl):16–21
 28. Bahn DK et al (2006) Focal prostate cryoablation: initial results 
show cancer control and potency preservation. J Endourol 
20(9):688–692
 29. Muto S et al (2008) Focal therapy with high-intensity-focused 
ultrasound in the treatment of localized prostate cancer. Jpn J 
Clin Oncol 38(3):192–199
 30. Fegoun ABE et al (2011) Focal therapy with high-intensity 
focused ultrasound for prostate cancer in the elderly. A feasibil-
ity study with 10 years follow-up. Int Braz J Urol 37(2):213–219 
discussion 220‑2
 31. Ahmed HU et al (2012) Focal therapy for localised unifocal and 
multifocal prostate cancer: a prospective development study. 
Lancet Oncol 13(6):622–632
 32. Dickinson L, Ahmed HA, McCartan N, Freeman A, Kirkham 
A, Allen C, Hindley R, Emberton M (2012) Medium term out-
comes following primary focal therapy using HIFU for localised 
prostate cancer. BJU Int 109(Suppl S7):6
 33. Van Velthoven R et al (2014) Primary zonal high intensity 
focused ultrasound for prostate cancer: results of a prospective 
phase IIa feasibility study. Prostate Cancer 2014:756189
 34. Berge V et al (2014) Morbidity associated with primary 
high intensity focused ultrasound and redo high inten-
sity focused ultrasound for localized prostate cancer. J Urol 
191(6):1764–1769
 35. Blana A et al (2006) Morbidity associated with repeated tran-
srectal high-intensity focused ultrasound treatment of localized 
prostate cancer. World J Urol 24(5):585–590
 36. Klotz L et al (2010) Clinical results of long-term follow-up of a 
large, active surveillance cohort with localized prostate cancer. J 
Clin Oncol 28(1):126–131
 37. Klotz L et al (2015) Long-term follow-up of a large active sur-
veillance cohort of patients with prostate cancer. J Clin Oncol 
33(3):272–277
 38. D’Alimonte L, Helou J, Sherman C, Loblaw A, Chung HT, 
Ravi A, Deabreu A, Zhang l, Morton G (2014) The clinical sig-
nificance of persistent cancer cells on prostate biopsy after high 
dose-rate brachytherapy boost for intermediate-risk prostate can-
cer. Brachytherapy. doi:10.1016/j.brachy.2014.10.003
 39. Zelefsky MJ et al (2008) Influence of local tumor control on dis-
tant metastases and cancer related mortality after external beam 
radiotherapy for prostate cancer. J Urol 179(4):1368–1373 dis‑
cussion 1373
 40. Yossepowitch O et al (2014) Positive surgical margins after radi-
cal prostatectomy: a systematic review and contemporary update. 
Eur Urol 65(2):303–313
964 World J Urol (2015) 33:955–964
1 3
 41. Onik G, Miessau M, Bostwick DG (2009) Three-dimensional 
prostate mapping biopsy has a potentially significant impact on 
prostate cancer management. J Clin Oncol 27(26):4321–4326
 42. Radtke JP, Kuru TH, Boxler S, Alt CD, Popeneciu IV, Huetten-
brink C, Klein T, Steinemann S, Bergstraesser C, Roethke M, 
Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA (2015) 
Comparative analysis of transperineal template saturation pros-
tate biopsy versus magnetic resonance imaging targeted biopsy 
with magnetic resonance imaging-ultrasound fusion guidance. J 
Urol 193(1):87–94. doi:10.1016/j.juro.2014.07.098
 43. Kasivisvanathan V et al (2013) Transperineal magnetic reso-
nance image targeted prostate biopsy versus transperineal tem-
plate prostate biopsy in the detection of clinically significant 
prostate cancer. J Urol 189(3):860–866
 44. Siddiqui MM et al (2013) Magnetic resonance imaging/ultra-
sound-fusion biopsy significantly upgrades prostate cancer ver-
sus systematic 12-core transrectal ultrasound biopsy. Eur Urol 
64(5):713–719
 45. Wysock JS et al (2014) A prospective, blinded comparison of 
magnetic resonance (MR) imaging-ultrasound fusion and visual 
estimation in the performance of MR-targeted prostate biopsy: 
the PROFUS trial. Eur Urol 66(2):343–351
 46. Cool DW et al (2015) Evaluation of MRI-TRUS fusion versus 
cognitive registration accuracy for MRI-targeted, TRUS-guided 
prostate biopsy. AJR Am J Roentgenol 204(1):83–91
 47. Crawford ED et al (2013) Clinical-pathologic correlation 
between transperineal mapping biopsies of the prostate and 
three-dimensional reconstruction of prostatectomy specimens. 
Prostate 73(7):778–787
 48. Hu Y et al (2012) A biopsy simulation study to assess the accu-
racy of several transrectal ultrasonography (TRUS)-biopsy 
strategies compared with template prostate mapping biopsies 
in patients who have undergone radical prostatectomy. BJU Int 
110(6):812–820
 49. Ross HM et al (2012) Do adenocarcinomas of the prostate with 
Gleason score (GS) </=6 have the potential to metastasize to 
lymph nodes? Am J Surg Pathol 36(9):1346–1352
 50. Eggener SE et al (2011) Predicting 15-year prostate cancer spe-
cific mortality after radical prostatectomy. J Urol 185(3):869–875
 51. Haffner MC et al (2013) Tracking the clonal origin of lethal 
prostate cancer. J Clin Investig 123(11):4918–4922
 52. Bostwick DG et al (1993) Staging of early prostate cancer: 
a proposed tumor volume-based prognostic index. Urology 
41(5):403–411
 53. Biermann K et al (2010) Histopathological findings after treat-
ment of prostate cancer using high-intensity focused ultrasound 
(HIFU). Prostate 70(11):1196–1200
 54. Muller BG et al (2014) Role of multiparametric magnetic reso-
nance imaging (MRI) in focal therapy for prostate cancer: a Del-
phi consensus project. BJU Int 114(5):698–707
 55. Punwani S et al (2014) Prostatic cancer surveillance following 
whole-gland high-intensity focused ultrasound: comparison of 
MRI and prostate-specific antigen for detection of residual or 
recurrent disease. Br J Radiol 2012(85):720–728
 56. Kim CK et al (2008) MRI techniques for prediction of local 
tumor progression after high-intensity focused ultrasonic abla-
tion of prostate cancer. AJR Am J Roentgenol 190(5):1180–1186
 57. Del Vescovo R et al (2013) Dynamic contrast-enhanced MR 
evaluation of prostate cancer before and after endorectal high-
intensity focused ultrasound. Radiol Med 118(5):851–862
 58. Rouviere O et al (2010) Prostate cancer transrectal HIFU abla-
tion: detection of local recurrences using T2-weighted and 
dynamic contrast-enhanced MRI. Eur Radiol 20(1):48–55
 59. Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, 
Bottomley D, Eggener S, Ehdaie B, Emberton M, Hindley R, 
Leslie T, Miners A, McCartan N, Moore CM, Pinto P, Polascik 
TJ, Simmons L, van der Meulen J, Villers A, Willis S, Ahmed 
HU (2015) Focal therapy: patients, interventions, and out-
comes—a report from a consensus meeting. Eur Urol 67(4):771–
777. doi:10.1016/j.eururo.2014.09.018
 60. Muller BG, van den Bos W, Brausi M, Fütterer JJ, Ghai S, Pinto 
PA, Popeneciu IV, de Reijke TM, Robertson C, de la Rosette 
JJ, Scionti S, Turkbey B, Wijkstra H, Ukimura O, Polascik TJ 
(2015) Follow-up modalities in focal therapy for prostate can-
cer: results from a Delphi consensus project. World J Urol 
14(2):e829–e829b. doi:10.1016/s1569-9056(15)60818-1
 61. van den Bos W et al (2014) Focal therapy in prostate cancer: 
international multidisciplinary consensus on trial design. Eur 
Urol 65(6):1078–1083
 62. Cooperberg MR et al (2010) Comparative risk-adjusted mor-
tality outcomes after primary surgery, radiotherapy, or andro-
gen-deprivation therapy for localized prostate cancer. Cancer 
116(22):5226–5234
 63. Zelefsky MJ et al (2010) Metastasis after radical prostatectomy 
or external beam radiotherapy for patients with clinically local-
ized prostate cancer: a comparison of clinical cohorts adjusted 
for case mix. J Clin Oncol 28(9):1508–1513
 64. Valerio M et al (2014) The role of focal therapy in the manage-
ment of localised prostate cancer: a systematic review. Eur Urol 
66(4):732–751
 65. Barqawi AB et al (2014) Targeted focal therapy in the manage-
ment of organ confined prostate cancer. J Urol 192:749–753
